| Publication Date | Title | Author(s) |
| 16-Aug-2019 | Achieving Greater Impact from Investments in Medicine in Canada | Waddell, K; Moat, KA; Lavis, JN; Gauvin, François-Pierre |
| 2000 | Barriers to employment-related healthy public policy | Lavis, JN; Farrant, Mark S. R.; Stoddart, G. L.; Centre for Health Economics and Policy Analysis |
| 1994 | Can we have too much health care? | Lavis, JN; Stoddart, G. L.; Centre for Health Economics and Policy Analysis |
| Aug-2019 | Citizen brief: Achieving greater impact from investments in medicine in Canada | Waddell, K; Moat, KA; Lavis, JN; Gauvin, François-Pierre |
| Nov-2016 | Citizen Brief: Addressing Health System Sustainability in Ontario | Waddell, K; Wilson, MG; Moat, KA; Lavis, JN |
| Jan-2015 | Citizen Brief: Addressing Nutritional Risk Among Older Adults in Ontario | Gauvin, François-Pierre; Lavis, JN; Bhuiya, AR; Mahendren, Mathura |
| Feb-2016 | Citizen Brief: Building a Primary-Care 'Home' for Every Ontarian | Wilson, MG; Lavis, JN; Moat, KA |
| Nov-2021 | Citizen brief: Creating resilient and responsive mental health systems for children, youth and families during and beyond the COVID-19 pandemic in Ontario | Alam, S; Gauvin, François-Pierre; Moat, KA; Lavis, JN; Lott, S |
| Jul-2016 | Citizen Brief: Defining the Mental Health and Addictions 'Basket of Core Services' to be Publicly Funded in Ontario | Waddell, K; Bullock, Heather; Lavis, JN |
| Jul-2016 | Citizen brief: Defining the mental health and addictions ‘basket of core services’ to be publicly funded in Ontario | Waddell, K; Bullock, H; Lavis, JN |
| Aug-2015 | Citizen Brief: Engaging Communities in Setting Priorities for Home and Community Care in Northeastern Ontario | Gauvin, François-Pierre; Lavis, JN; Warry, Wayne; Neufeld, Eva |
| Nov-2019 | Citizen brief: Engaging older adults with complex health and social needs, and their caregivers, to improve hospital-to-home transitions in Ontario | Gauvin, François-Pierre; Ganann, R; Heald-Taylor, G; Markle-Reid, M; McAiney, C; Moat, KA; Lavis, JN |
| Mar-2020 | Citizen brief: Engaging patients, families and caregivers to support Ontario Health Teams | Gauvin, François-Pierre; Waddell, K; Dion, A; Lavis, JN; Abelson, J; Bullock, H |
| Oct-2016 | Citizen Brief: Enhancing Access to Patient-centred Primary Care in Ontario | Wilson, MG; Waddell, K; Lavis, JN |
| Apr-2019 | Citizen brief: Enhancing the delivery of comprehensive care for people living with HIV in Canada | Wilson, MG; Mattison, CA; Gao, C; Kendall, CE; Lavis, JN |
| Oct-2015 | Citizen Brief: Exploring Models for Pharmacist Prescribing in Ontario | Gauvin, François-Pierre; Lavis, JN; McCarthy, Lisa |
| Jan-2021 | Citizen brief: Identifying and harnessing the potential of technology in long-term care settings in Canada | Gauvin, François-Pierre; DeMaio, P; Alam, S; Drakos, A; Lavis, JN; Wilson, MG |
| Nov-2013 | Citizen Brief: Improving Access to Palliative Care in Ontario | Gauvin, François-Pierre; Abelson, Julia; Lavis, JN |
| Feb-2014 | Citizen Brief: Improving Care and Support for People with Multiple Chronic Health Conditions in Ontario | Gauvin, François-Pierre; Wilson, MG; Lavis, JN; Abelson, J |
| Nov-2013 | Citizen Brief: Improving End-of-Life Communication and Decision-making in Ontario | Gauvin, François-Pierre; Abelson, Julia; Lavis, JN |
| Aug-2014 | Citizen Brief: Meeting the Future Home and Community Care Needs of Older Adults in Ontario | Wilson, MG; Gauvin, François-Pierre; Lavis, JN |
| Aug-2015 | Citizen Brief: Mobilisation des collectivités dans l'établissement des priorités pour les soins à domicile et les soins communautaires dans le Nord-Est de l'Ontario | Gauvin, François-Pierre; Lavis, JN; Neufeld, Eva |
| Aug-2017 | Citizen Brief: Modernizing the Oversight of the Health Workforce in Ontario | Waddell, K; Moat, KA; Lavis, JN |
| Mar-2018 | Citizen brief: Optimizing patient and family transitions from cancer treatment to primary- and community-care supports in Canada | Mattison, CA; Moat, KA; Waddell, K; Lavis, JN |
| Sep-2016 | Citizen Brief: Planning for the Future Health Workforce of Ontario | Moat, KA; Ciurea, I; Waddell, K; Lavis, JN |
| Oct-2022 | Citizen brief: Putting evidence at the centre of everyday life in Ontario | Gauvin, François-Pierre; Moat, KA; Smith, M; Irons, A; Lavis, JN |
| Sep-2018 | Citizen brief: Reducing emergency department usage in people with inflammatory bowel disease in provincial health systems in Canada | Mattison, CA; Moat, KA; Scallan, Eilish; Lavis, JN; Gauvin, François-Pierre |
| Nov-2014 | Citizen Brief: Sharing Health Information with Older Adults through Online Resources in Canada | Moat, KA; Gauvin, François-Pierre; Lavis, JN |
| Apr-2016 | Citizen Brief: Strengthening Care for People with Chronic Diseases in Ontario | Wilson, MG; Lavis, JN; Moat, KA; Guta, A |
| Feb-2018 | Citizen Brief: Strengthening Collaboration to Optimize Efforts Addressing Gambling-related Harm in Ontario | Waddell, K; Moat, KA; Lavis, JN; Bullock, Heather |
| Jan-2020 | Citizen brief: Supporting rapid learning and improvement for select conditions in Canada | Bhuiya, AR; Moat, KA; Lavis, JN |
| Sep-2017 | Citizen Brief: Taking a Step Towards Achieving Worry-free Surgery in Ontario | Gauvin, François-Pierre; Wilson, MG; Lavis, JN |
| Nov-2022 | Citizen brief: Using remote-monitoring technologies to enable people to stay in their homes in Canada | Gauvin, François-Pierre; Wilson, MG; Lavis, JN |
| Jan-2021 | COVID-19 living evidence profile #1 (version 1.2): What is known about anticipated COVID-19 vaccine roll-out elements? | Wilson, MG; Bain, T; Wang, Q; Al-Khateeb, S; Bhuiya, AR; Alam, S; DeMaio, P; Gauvin, François-Pierre; Ahmad, A; Drakos, A; Sharma, K; Whitelaw, S; Lavis, JN |
| Feb-2021 | COVID-19 living evidence profile #1 (version 1.3): What is known about anticipated COVID-19 vaccine roll-out elements? | Wilson, MG; Bain, T; Wang, Q; Al-Khateeb, S; Bhuiya, AR; Alam, S; DeMaio, P; Gauvin, François-Pierre; Ahmad, A; Drakos, A; Sharma, K; Whitelaw, S; Lavis, JN |
| Feb-2021 | COVID-19 living evidence profile #1 (version 1.4): What is known about anticipated COVID-19 vaccine roll-out elements? | Wilson, MG; Bain, T; Wang, Q; Al-Khateeb, S; Bhuiya, AR; Alam, S; DeMaio, P; Gauvin, François-Pierre; Ahmad, A; Drakos, A; Sharma, K; Whitelaw, S; Lavis, JN |
| Mar-2021 | COVID-19 living evidence profile #1 (version 1.5): What is known about anticipated COVID-19 vaccine roll-out elements? | Wilson, MG; Bain, T; Wang, Q; Al-Khateeb, S; Bhuiya, AR; Alam, S; DeMaio, P; Gauvin, François-Pierre; Ahmad, A; Drakos, A; Sharma, K; Whitelaw, S; Lavis, JN |
| Apr-2021 | COVID-19 living evidence profile #1 (version 1.6): What is known about anticipated COVID-19 vaccine roll-out elements? | Bhuiya, AR; Bain, T; Wang, Q; Al-Khateeb, S; Alam, S; DeMaio, P; Gauvin, François-Pierre; Ahmad, A; Drakos, A; Rintjema, J; Sharma, K; Santesso, N; Lavis, JN; Wilson, MG |
| May-2021 | COVID-19 living evidence profile #1 (version 1.7): What is known about anticipated COVID-19 vaccine roll-out elements? | Bhuiya, AR; Bain, T; Wang, Q; Al-Khateeb, S; DeMaio, P; Ahmad, A; Drakos, A; Rintjema, J; Sharma, K; Matthews, M; Gauvin, François-Pierre; Lavis, JN; Wilson, MG |
| Mar-2021 | COVID-19 living evidence profile #2 (version 2.2): What is known about preventing and managing COVID-19, outbreaks of COVID-19, and about supporting renewal in long-term care homes? | Waddell, K; DeMaio, P; Wilson, MG; Bain, T; Wang, Q; Al-Khateeb, S; Alam, S; Sharma, K; Whitelaw, S; Gauvin, François-Pierre; Lavis, JN |
| Apr-2021 | COVID-19 living evidence profile #2 (version 2.3): What is known about preventing and managing COVID-19, outbreaks of COVID-19, and about supporting renewal in long-term care homes? | Waddell, K; DeMaio, P; Wilson, MG; Bain, T; Wang, Q; Al-Khateeb, S; Alam, S; Sharma, K; Whitelaw, S; Gauvin, François-Pierre; Lavis, JN |
| Jul-2021 | COVID-19 living evidence profile #2 (version 2.4): What is known about preventing and managing COVID-19, outbreaks of COVID-19, and about supporting renewal in long-term care homes? | Waddell, K; DeMaio, P; Wilson, MG; Bain, T; Wang, Q; Al-Khateeb, S; Alam, S; Sharma, K; Whitelaw, S; Gauvin, François-Pierre; Lavis, JN |
| Oct-2021 | COVID-19 living evidence profile #2 (version 2.5): What is known about supporting renewal in long-term care homes? | Waddell, K; Wilson, MG; Bain, T; Bhuiya, AR; Al-Khateeb, S; Lavis, JN |
| May-2021 | COVID-19 living evidence profile #3 (version 3.1): What is known about how schools (K-12) and postsecondary institutions (colleges and universities) adjust COVID-19 transmission-mitigation measures as infection rates change and vaccination rates increase? | Bain, T; Bhuiya, AR; Al-Khateeb, S; Wang, Q; Mansilla, C; Rintjema, J; DeMaio, P; Alam, S; Gauvin, François-Pierre; Santesso, N; Lavis, JN; Wilson, MG |
| Jun-2021 | COVID-19 living evidence profile #3 (version 3.2): What is known about how schools (K-12) and postsecondary institutions (colleges and universities) adjust COVID-19 transmission-mitigation measures as infection rates change and vaccination rates increase? | Bain, T; Bhuiya, AR; Al-Khateeb, S; Wang, Q; Mansilla, C; DeMaio, P; Rintjema, J; Abeer, A; Gauvin, François-Pierre; Matthews, M; Lavis, JN; Wilson, MG |
| Sep-2021 | COVID-19 living evidence profile #3 (version 3.3): What is known about how schools (K-12) and post-secondary institutions (colleges and universities) adjust COVID-19 transmission-mitigation measures as infection rates change and vaccination rates increase? | Bain, T; Bhuiya, AR; Al-Khateeb, S; Wang, Q; Mansilla, C; Rintjema, J; DeMaio, P; Matthews, M; Lavis, JN; Wilson, MG |
| May-2021 | COVID-19 living evidence profile #4 (version 4.1): What went well and what could have gone better in the COVID-19 response in Canada, as well as what will need to go well in future given any available foresight work being conducted? | Waddell, K; Wilson, MG; Bain, T; Bhuiya, AR; Al-Khateeb, S; Sharma, K; DeMaio, P; Lavis, JN |
| Jun-2021 | COVID-19 living evidence profile #4 (version 4.2): What went well and what could have gone better in the COVID-19 response in Canada, as well as what will need to go well in future given any available foresight work being conducted? | Waddell, K; Wilson, MG; Bain, T; Bhuiya, AR; Al-Khateeb, S; Sharma, K; DeMaio, P; Lavis, JN |
| Jul-2021 | COVID-19 living evidence profile #4 (version 4.3): What went well and what could have gone better in the COVID-19 responses, as well as what will need to go well in future given any available foresight work being conducted? | Waddell, K; Wilson, MG; Bain, T; Bhuiya, AR; Al-Khateeb, S; Sharma, K; DeMaio, P; Lavis, JN |
| Aug-2021 | COVID-19 living evidence profile #4 (version 4.4): What went well and what could have gone better in the COVID-19 responses, as well as what will need to go well in future given any available foresight work being conducted? | Waddell, K; Wilson, MG; Bain, T; Bhuiya, AR; Al-Khateeb, S; Sharma, K; DeMaio, P; Lavis, JN |
| Jun-2021 | COVID-19 living evidence profile #5 (version 5.1): What went well and what could have gone better in the COVID-19 response in other countries, as well as what will need to go well in future given any available foresight work being conducted? | Waddell, K; Wilson, MG; Bain, T; Bhuiya, AR; Al-Khateeb, S; Sharma, K; DeMaio, P; Lavis, JN |
| Jul-2021 | COVID-19 living evidence profile #5 (version 5.2): What went well and what could have gone better in the COVID-19 response in other countries, as well as what will need to go well in future given any available foresight work being conducted? | Waddell, K; Wilson, MG; Bain, T; Bhuiya, AR; Al-Khateeb, S; Sharma, K; DeMaio, P; Bierman, O; Lavis, JN |
| Aug-2021 | COVID-19 living evidence profile #5 (version 5.3): What went well and what could have gone better in the COVID-19 response in other countries, as well as what will need to go well in future given any available foresight work being conducted? | Waddell, K; Wilson, MG; Bain, T; Bhuiya, AR; Al-Khateeb, S; Sharma, K; DeMaio, P; Biermann, O; Lavis, JN |
| Apr-2021 | COVID-19 living evidence synthesis #6 (version 6.2): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Sep-2021 | COVID-19 living evidence synthesis #6 (version 6.20): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Oct-2021 | COVID-19 living evidence synthesis #6 (version 6.21): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Oct-2021 | COVID-19 living evidence synthesis #6 (version 6.22): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Nov-2021 | COVID-19 living evidence synthesis #6 (version 6.23): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Nov-2021 | COVID-19 living evidence synthesis #6 (version 6.24): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Dec-2021 | COVID-19 living evidence synthesis #6 (version 6.25): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Dec-2021 | COVID-19 living evidence synthesis #6 (version 6.26): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Jan-2022 | COVID-19 living evidence synthesis #6 (version 6.27): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Jan-2022 | COVID-19 living evidence synthesis #6 (version 6.28): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Feb-2022 | COVID-19 living evidence synthesis #6 (version 6.29): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Apr-2021 | COVID-19 living evidence synthesis #6 (version 6.3): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Feb-2022 | COVID-19 living evidence synthesis #6 (version 6.30): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Mar-2022 | COVID-19 living evidence synthesis #6 (version 6.33): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Apr-2022 | COVID-19 living evidence synthesis #6 (version 6.34): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Apr-2022 | COVID-19 living evidence synthesis #6 (version 6.35): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| May-2022 | COVID-19 living evidence synthesis #6 (version 6.36): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| May-2022 | COVID-19 living evidence synthesis #6 (version 6.37): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Jun-2022 | COVID-19 living evidence synthesis #6 (version 6.38): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Jul-2022 | COVID-19 living evidence synthesis #6 (version 6.39): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
| Apr-2020 | COVID-19 rapid evidence profile # 2: What is known about the spread and management of COVID-19 in non-health workplaces? | Waddell, K; Gauvin, François-Pierre; Wilson, MG; Moat, KA; Mansilla, C; Lavis, JN |
| May-2020 | COVID-19 rapid evidence profile #10: What screening approaches can be used in non-healthcare settings (e.g., universities, stores and office settings) to identify people who may have COVID-19 and need to take appropriate action? | Wilson, MG; Waddell, K; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Lavis, JN |
| May-2020 | COVID-19 rapid evidence profile #11: What is the evidence related to playground equipment and risk of COVID-19 transmission? | Waddell, K; Wilson, MG; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Voorheis, P; Bhuiya, AR; Ahmad, A; Sharma, K; Lavis, JN |
| Jun-2020 | COVID-19 rapid evidence profile #12: What insights from the available evidence and jurisdictional scans can inform who should be tested for COVID-19 and how frequently, where, by whom and with what follow-up actions should they be tested? | Wilson, MG; Waddell, K; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Voorheis, P; Bhuiya, AR; Ahmad, A; Lavis, JN |
| Jun-2020 | COVID-19 rapid evidence profile #13: What pandemic-related mental health and addictions issues have emerged and what indicators and strategies can be used to monitor and address them, respectively? | Waddell, K; Wilson, MG; Bullock, HL; Evans, C; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Voorheis, P; Bhuiya, AR; Ahmad, A; Lavis, JN |
| Jun-2020 | COVID-19 rapid evidence profile #14: Where and with what impacts have shifts from in-person to virtual approaches occurred in the delivery of healthcare services in general and mental health and addictions services in particular? | Waddell, K; Bullock, HL; Evans, C; Wilson, MG; Gauvin, François-Pierre; Moat, KA; Mansilla, C; Wang, Q; Bhuiya, AR; Ahmad, A; Filbey, L; Lavis, JN |
| Jul-2020 | COVID-19 rapid evidence profile #15: What frameworks from available evidence and experiences in other countries can inform what needs to be done to plan for future waves of COVID-19? | Wilson, MG; Waddell, K; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Bhuiya, AR; Voorheis, P; Ahmad, A; Gao, C; Alam, S; Lavis, JN |
| Jul-2020 | COVID-19 rapid evidence profile #16: What provider-led virtual-care services can be used to replace in-person care in hospital-based ambulatory care settings? | Wilson, MG; Waddell, K; Wang, Q; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Ahmad, A; Alam, S; Bhuiya, AR; Lavis, JN |
| Aug-2020 | COVID-19 rapid evidence profile #17: What evidence could support modelling scenarios related to the reopening, operation and monitoring of schools? | Wilson, MG; Waddell, K; Moat, KA; Wang, Q; Ahmad, A; Alam, S; Bhuiya, AR; Sharma, K; Lavis, JN |
| Sep-2020 | COVID-19 rapid evidence profile #19: What is the risk of transmission of COVID-19 in hospital and long-term care settings, and the impacts of hospital-visitor policies? | Waddell, K; Wilson, MG; Moat, KA; Wang, Q; Gauvin, François-Pierre; Ahmad, A; Alam, S; Bhuiya, AR; Tchakerian, N; Lavis, JN |
| Apr-2020 | COVID-19 rapid evidence profile #1: What is known about approaches to and safety of conserving, reusing, and repurposing different kinds of masks? | Wilson, MG; Gauvin, François-Pierre; Waddell, K; Moat, KA; Lavis, JN |
| Oct-2020 | COVID-19 rapid evidence profile #20: What living, full or rapid reviews have been produced that provide evidence about economic and social responses to COVID-19? | Wilson, MG; Waddell, K; Moat, KA; Wang, Q; Lavis, JN |
| Oct-2020 | COVID-19 rapid evidence profile #21: What is the impact of the pandemic on substance use (particularly, alcohol and opioid use) in the population, and what policy decisions have been adopted that affect the availability and use of substances, as well as services for people who use substances? | Bullock, H; Waddell, K; Bhuiya, AR; Wilson, MG; Gauvin, François-Pierre; Moat, KA; Alam, S; Lavis, JN |
| Oct-2020 | COVID-19 rapid evidence profile #22: What is known about whether vaccine injury-compensation programs and program elements affect vaccine acceptance and uptake? | Bhuiya, AR; Waddell, K; Moat, KA; Wilson, MG; Gauvin, François-Pierre; Whitelaw, S; Alam, S; Sharma, K; Drakos, A; Lavis, JN |
| Nov-2020 | COVID-19 rapid evidence profile #23: What is known about anticipated COVID-19 vaccine-delivery program elements, and whether and how federated states are harmonizing these elements across constituent units of federations? | Bhuiya, AR; Wilson, MG; Moat, KA; Gauvin, François-Pierre; Wang, Q; Whitelaw, S; Alam, S; Sharma, K; Ahmad, A; Drakos, A; Dren, N; Bain, T; Lavis, JN |
| Nov-2020 | COVID-19 rapid evidence profile #24: What is known about strategies for encouraging vaccine acceptance and addressing vaccine hesitancy (including efforts to combat misinformation that may lead to vaccine hesitancy) or uptake (when interpreted, at least in part, through the perspective of vaccine acceptance or hesitancy)? | Gauvin, François-Pierre; Lavis, JN |
| Jan-2021 | COVID-19 rapid evidence profile #25: What do we know from both research and jurisdictional scans about prioritizing vaccination of asymptomatic residents in a long-term care home with an outbreak? | Wang, Q; Wilson, MG; Alam, S; Ahmad, A; Bain, T; Bhuiya, AR; Drakos, A; Sharma, K; Whitelaw, S; Bain, T; Lavis, JN |
| Mar-2021 | COVID-19 rapid evidence profile #26: When and in what order can COVID-19-related public-health measures be lifted (or stringency be reduced) as vaccination rates and seasonal temperatures increase? | Wilson, MG; Bain, T; Wang, Q; Al-Khateeb, S; Bhuiya, AR; Alam, S; DeMaio, P; Gauvin, François-Pierre; Ahmad, A; Sharma, K; Whitelaw, S; Lavis, JN |
| Jan-2022 | COVID-19 rapid evidence profile #27: What measures and approaches can protect the most vulnerable in hospitals when outbreaks of Omicron in hospital are becoming more common? | Wilson, MG; Bhuiya, AR; Bain, T; Al-Khateeb, S; Mansilla, C; Mehta, V; Sood, T; Soueidan, S; Rintjema, J; Waddell, K; Wang, A; Wang, Q; Wang, X; Lavis, JN |
| Jan-2022 | COVID-19 rapid evidence profile #28: What is the filtration performance of KN95 masks compared to surgical and N95 masks, and how can their use be optimized in hospital settings? | Al-Khateeb, S; Bain, T; Bhuiya, AR; Mansilla, C; Mehta, V; Sood, T; Wang, Q; Soueidan, S; Rintjema, J; Wang, A; Lavis, JN; Wilson, MG |
| Apr-2020 | COVID-19 rapid evidence profile #3: What is the evidence about international and Canadian experiences with asymptomatic screening to identify COVID-19 cases and to prevent transmission? | Wilson, MG; Waddell, K; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Lavis, JN |
| Apr-2020 | COVID-19 rapid evidence profile #4: What are the most effective non-medical masks for preventing community transmission of COVID-19, and should they be required for all of society? | Wilson, MG; Gauvin, François-Pierre; Moat, KA; Waddell, K; Mansilla, C; Wang, Q; Lavis, JN |
| Apr-2020 | COVID-19 rapid evidence profile #5: What is known about the use of medical masks by essential non-medical workers to prevent community transmission of COVID-19? | Waddell, K; Gauvin, François-Pierre; Wilson, MG; Moat, KA; Mansilla, C; Wang, Q; Lavis, JN |
| Apr-2020 | COVID-19 rapid evidence profile #6: What is known about strategies for supporting the use of masks under shortage conditions to prevent COVID-19? | Waddell, K; Wilson, MG; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Lavis, JN |
| May-2020 | COVID-19 rapid evidence profile #7: What are the international lessons learned from re-opening non-COVID-19 activities in hospitals? | Waddell, K; Wilson, MG; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Lavis, JN |
| May-2020 | COVID-19 rapid evidence profile #8: How effective is temperature taking at borders or in general as a screening tool to identify people who may have COVID-19 and need to take appropriate action? | Wilson, MG; Waddell, K; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Lavis, JN |
| May-2020 | COVID-19 rapid evidence profile #9: What is the incremental benefit of using a history of sudden loss of taste (ageusia) and/or smell (anosmia) in symptom screening to identify people who may have COVID-19 and need to take appropriate action? | Waddell, K; Wilson, MG; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Lavis, JN |
